DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lucentis (Ranibizumab) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

LUCENTIS SUMMARY

LUCENTIS(ranibizumab injection)

LUCENTIS (ranibizumab injection) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use.   Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF‑A).

LUCENTIS is indicated for the treatment of patients with neovascular (wet) age‑related macular degeneration.


See all Lucentis indications & dosage >>

LUCENTIS NEWS HIGHLIGHTS

Media Articles Related to Lucentis (Ranibizumab)

Ranibizumab Injections Reduce Retinal Swelling
Source: MedicineNet Edema Specialty [2008.05.02]

Gene Linked to 'Dry' Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2008.08.28]

Macular Degeneration (Age-Related Type)
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2007.12.27]

Brain Reorganizes To Adjust For Loss Of Vision
Source: Eye Health / Blindness News From Medical News Today [2008.11.21]

more >>

Published Studies Related to Lucentis (Ranibizumab)

Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. [2008.10]

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. [2007.10]

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. [2007.02]

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. [2006.11]

Ranibizumab versus verteporfin for neovascular age-related macular degeneration. [2006.10.05]

more >>

Clinical Trials Related to Lucentis (Ranibizumab)

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema [Recruiting]

Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-Related Macular Degeneration (AMD) [Recruiting]

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-Based Retreatment [Recruiting]

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration [Not yet recruiting]

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization [Recruiting]

more >>

Page last updated: 2008-11-21

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008